ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1572

Plasma Apolipoprotein B48 Levels in Patients with Rheumatoid Arthritis: Evaluating Novel Cardiovascular Risk Factors

Deborah van Breukelen-van der Stoep1, Derkjen van Zeben1, Marijke de Vries2, Boudewijn Klop2, Noelle van der Meulen2, Gert Jan van de Geijn3, Hans Janssen3, Pedro Valdivielso4, José Rioja4, José Ramirez-Bollero4, Mieke Hazes5, Erwin Birnie6,7 and Manuel Castro Cabezas8, 1Department of Rheumatology, Sint Franciscus Gasthuis, Rotterdam, Netherlands, 2Department of Internal Medicine, Sint Franciscus Gasthuis, Rotterdam, Netherlands, 3Department of Clinical Chemistry, Sint Franciscus Gasthuis, Rotterdam, Netherlands, 4Department of Internal Medicine and Dermatology, Hospital Virgen de la Victoria, Malaga, Spain, 5Department of Rheumatology, Erasmus Medical Centre Rotterdam, Rotterdam, Netherlands, 6Statistics and Education, Sint Franciscus Gasthuis, Rotterdam, Netherlands, 7Insitute of Health Policy and Management, Erasmus University, Rotterdam, Netherlands, 8Department of Internal Medicine, Sint Francicscus Gasthuis, Rotterdam, Netherlands

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Atherosclerosis, Cardiovascular disease and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 9, 2015

Title: Rheumatoid Arthritis - Clinical Aspects Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Chylomicrons, with apolipoprotein (apo) B48 as a structural protein, induce leukocyte and complement activation and contribute to atherosclerosis. ApoB48 is higher in conditions associated with a higher degree of systemic inflammation and apoB48 helps to identify patients at increased cardiovascular risk. There are no data available on apoB48 levels in rheumatoid arthritis (RA) in relation to atherosclerosis. Since classical risk factors do not predict the cardiovascular risk well in RA, search for novel markers of risk is relevant. The objective of this study was to investigate the levels of apoB48 in RA patients compared to patients with coronary artery disease (CAD) and its association with metabolic and other lipid parameters, carotid intima media thickness (cIMT) and the estimated cardiovascular risk.

Methods: RA patients, without the presence of clinical cardiovascular disease or diabetes mellitus and participating in the FRANCIS study, were included. Also subjects with CAD (CAD+) and without RA were included. Blood samples were collected after an overnight fast and a complete lipid profile, including total plasma apoB and apoB48 (ELISA) were measured. cIMT was measured using ultrasound.

Results: 328 Patients with RA and 56 CAD+ patients were included. RA patients were younger (53±11 vs. 68±11 yrs; P<0.001), more often female (68% vs. 34%; P<0.001) and had lower remnant cholesterol (remnant-C) concentrations (0.52±0.26 vs. 0.75±34 mmol/l; P<0.001) and triglycerides (1.25±0.88 vs. 1.83±1.12 mmol/l; P<0.001) compared to CAD+ patients. Median apoB48 was significantly higher in RA patients compared to CAD+ patients (8.6 [IQR 5.2-12.5] vs. 7.1 [IQR 4.9-10.4] mg/L; P=0.026). In RA apoB48 correlated positively with triglycerides (r=0.616; P<0.001), remnant-C (r=0.479; P<0.001), LDL-cholesterol (r=0.123; P=0.03) and the cardiovascular risk score according to the SCORE model (r=0,141; P=0.011). No significant correlation between apoB48 and cIMT (r=0.103; P=0.07), BMI (r=0.014; P=0.81), systolic blood pressure (r=0.095; P=0.09), glucose (r=0.106; p=0.06)and RA DAS28 (-0.32; P=0.58) was found.

Conclusion: In RA apoB48 is associated with an increased cardiovascular risk score and may contribute to the increased atherogenesis of RA. Since apoB48 in RA was higher compared to CAD+ patients, despite lower triglycerides and remnant-C, chylomicron remnant clearance may be impaired in RA.


Disclosure: D. van Breukelen-van der Stoep, None; D. van Zeben, None; M. de Vries, None; B. Klop, None; N. van der Meulen, None; G. J. van de Geijn, None; H. Janssen, None; P. Valdivielso, None; J. Rioja, None; J. Ramirez-Bollero, None; M. Hazes, None; E. Birnie, None; M. Castro Cabezas, None.

To cite this abstract in AMA style:

van Breukelen-van der Stoep D, van Zeben D, de Vries M, Klop B, van der Meulen N, van de Geijn GJ, Janssen H, Valdivielso P, Rioja J, Ramirez-Bollero J, Hazes M, Birnie E, Castro Cabezas M. Plasma Apolipoprotein B48 Levels in Patients with Rheumatoid Arthritis: Evaluating Novel Cardiovascular Risk Factors [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/plasma-apolipoprotein-b48-levels-in-patients-with-rheumatoid-arthritis-evaluating-novel-cardiovascular-risk-factors/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/plasma-apolipoprotein-b48-levels-in-patients-with-rheumatoid-arthritis-evaluating-novel-cardiovascular-risk-factors/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology